Home
Conditions
Carcinoma, Non-Small-Cell Lung

Clinical trial condition

Carcinoma, Non-Small-Cell Lung

Explore clinical trials studying Carcinoma, Non-Small-Cell Lung. Study availability and eligibility vary by location and protocol.

4,689 public trials 1,036 recruiting studies

Refine in advanced search Browse all conditions

Carcinoma, Non-Small-Cell Lung trial results

Recruiting

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

NCT06579196

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: University of Nebraska Medical Center Omaha, Nebraska, United States

View Trial Details

Recruiting

Copenhagen Master Observational Trial

NCT05145244

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +13 more
Locations: Rigshospitalet Copenhagen, Denmark

View Trial Details

Recruiting

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

NCT06951464

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: West China Hospital, Sichuan University Chengdu, Sichuan, China

View Trial Details

Recruiting

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

NCT07008287

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: Zhejiang Cancer Hospital Hangzhou, Zhejiang, China

View Trial Details

Recruiting

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

NCT04136535

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: Caner hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Uninon Medical college Shenzhen, shenzhen, China

View Trial Details

Recruiting

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

NCT06709859

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations: Shandong Public Health Clinical Center Jinan, Shangdong, China

View Trial Details

Recruiting

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

NCT06962865

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: Beijing Chest Hospital,Capital Medical Unniversity Beijing, China

The Fifth Medical Center of Chinese People's Liberation Army General Hospital Beijing, China

Binzhou Medical University Hospital Binzhou, China

Jilin Cancer Hospital Changchun, China

View all 34 locations

View Trial Details

Recruiting

Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.

NCT06167460

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +12 more
Locations: Medical Genetics Institute Ho Chi Minh City, Vietnam

View Trial Details

Recruiting

An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment

NCT05486650

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: the second affiliated hospital of Army medical university Chongqing, Chongqing Municipality, China

View Trial Details

Recruiting

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

NCT06379087

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: Zhejiang Cancer Hospital Hangzhou, Zhejiang, China

View Trial Details

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung trial results

Related conditions